NCT03400826View on ClinicalTrials.gov

Effects of Simvastatin on Uterine Leiomyoma Size

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Fibroid UterusFibroid TumorLeiomyomaFibromyomaLeiomyoma, Uterine
Interventions
DRUG

Simvastatin 40mg

The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.

DRUG

Placebo 40 mg

The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.

Trial Locations (1)

21218

RECRUITING

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Johns Hopkins University

OTHER